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CD70-restricted specific activation of TRAILR1
or TRAILR2 using scFv-targeted TRAIL mutants
J Trebing1, M El-Mesery1,2, V Scha¨fer1, D Weisenberger1, D Siegmund1, K Silence3 and H Wajant*,1
To combine the CD27 stimulation inhibitory effect of blocking CD70 antibodies with an antibody-dependent cellular cytotoxicity
(ADCC)-independent, cell death-inducing activity for targeting of CD70-expressing tumors, we evaluated here fusion proteins of
the apoptosis-inducing TNF family member TRAIL and a single-chain variable fragment (scFv) derived from a high-affinity
llama-derived anti-human CD70 antibody (lahCD70). A fusion protein of scFv:lahCD70 with TNC-TRAIL, a stabilized form of
TRAIL, showed strongly enhanced apoptosis induction upon CD70 binding and furthermore efficiently interfered with
CD70-CD27 interaction. Noteworthy, introduction of recently identified mutations that discriminate between TRAILR1 and
TRAILR2 binding into the TRAIL part of scFv:lahCD70-TNC-TRAIL resulted in TRAIL death receptor-specific fusion proteins
with CD70-restricted activity.
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CD70 (CD27L) is a typical member of the tumor necrosis
factor (TNF) family and thus occurs primarily as a trimeric type
II transmembrane protein. CD70 expression is normally
restricted to B cells, mature dendritic cells and activated
T cells.1,2 CD70 interacts with CD27, a member of the TNF
receptor superfamily that is expressed on a subset of B-cells,
NK and NKT cells but especially on various types of T cells.1,2
Although there is some evidence that CD70 itself directly
triggers intracellular signaling in CD70þ cells in response to
CD27 binding (reverse signaling), the huge majority of CD70-
mediated effects are based on activation of CD27-associated
signaling pathways. Unusual for a member of the TNF
receptor family, CD27 is expressed as a disulfide-bonded
homodimer instead as amonomer, although there is evidence
that at least some of the ‘normal’ monomeric TNF receptor
types also undergo auto-aggregationwith the help of a pre-ligand
assembly domain (PLAD) in their extracellular domain.3,4
CD27 stimulation results in recruitment of Siva-1, a poorly
understood apoptosis regulatory molecule, and of the adapter
protein E3 ligases TRAF2 and TRAF5.5–8 In accordance with
the established role of TRAF2 and TRAF5 in NFkB signaling,
CD27 activation results in enhanced activity of the classical
and alternative NFkB pathway, which both has been implicated
in survival, activation and differentiation of T cells.9,10
CD70 is also strongly expressed with high frequency in a
variety of hematologic malignancies and surprisingly often in
solid tumors, especially in clear cell renal cell carcinoma but
also frequently (10–25%) in pancreatic, larynx, ovarian and
colon cancer, glioblastoma and melanoma.11–14 The reasons
and functional relevance of CD70 expression in transformed
cells are yet poorly understood and may differ from case to
case. At the first glance, the expression of CD70 on tumor
cells appears counterintuitive as this should result in
enhanced antigenicity of the tumor. Indeed, it has been
demonstrated in animal models that treatment with agonistic
CD27 antibodies or vaccinia virus-delivered CD70 enhances
anti-tumor T-cell responses.15–18 Furthermore, it has been
demonstrated that CD70-secreting tumor cells induce
an enhanced anti-tumor immune response.19,20 However,
especially in situations of persistent CD70 expression,
immune inhibitory effects may also appear, because of
exhaustion of the T-cell pool and there is further evidence
that tumor cells expressing CD70 increase the amount of
Tregs in the tumor microenvironment.21,22 Irrespective from
its concrete function in the tumor cell, due to its quite restricted
expression on non-transformed tissue, CD70 can be con-
sidered as an excellent target for therapeutic antibodies. It is
therefore no surprise that CD70-specific antibodies are under
clinical and preclinical investigation for the treatment of
autoimmune diseases and cancer23 (http://clinicaltrials.gov/).
With respect to CD70 targeting in cancer, two conceptions
are of particular relevance: first, the very well-established idea
to exploit CD70 as a tumor marker to direct ADCC-inducing
antibodies or antibody–drug conjugates to themalignant cells,
which is already in clinical trials, and, second, the relatively
new strategy to block the putative immune inhibitory effects of
tumor cell-expressed CD70. Although the latter aim could be
similarly achieved by ADCC-mediated tumor cell destruction,
CD70-blocking antibodies may elicit these effects also at
lower concentrations insufficient to compensate for the
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inhibitory effect of the endogenously present serum IgG or in
the presence of ADCC inhibitory signals/molecules.
TNF-related apoptosis-inducing ligand (TRAIL) is a member
of the TNF ligand family with potent apoptosis-inducing
properties and attracts considerable interest due to its
potential use for tumor therapy.24,25 This is because of the
finding that most nontransformed cells are for various reasons
protected from TRAIL-induced apoptosis, whereas many
transformed cells are TRAIL sensitive. Similar to other TNF
ligands, TRAIL is initially expressed as a membrane-bound
trimeric ligand that signals apoptosis by activation of the death
receptors TRAILR1 and TRAILR2. The soluble ectodomain of
TRAIL also assembles into trimeric molecules but is in
contrast to the membrane-bound molecule poorly active
despite receptor binding.26,27 It has been shown that the poor
responsiveness of TRAIL death receptors (particular of
TRAILR2) toward soluble TRAIL trimers can be overcome in
two ways. First, by oligomerization of two or more TRAIL
trimers or second by artificial cell surface immobilization, for
example, by fusing soluble TRAIL to a single-chain variable
fragment (scFv) of an antibody specific for a cell surface-
exposed antigen.28 Noteworthy, the latter principle not only
allows potent TRAIL death receptor activation but also makes
this activation dependent on cell surface antigen binding.
Thus, by use of tumor marker-specific scFvs for generation of
scFv-TRAIL fusion proteins, tumor-restricted TRAIL death
receptor activity can be achieved.28
Dulanermin, a recombinant form of soluble TRAIL, has
been evaluated in clinical trials and showed a good safety
profile but also lack of efficacy.24,29 Against the background
of the limited activity of soluble TRAIL, it appears indeed
unlikely that Dulanermin unleashes the full apoptosis-inducing
capacity of the TRAIL death receptors. There is a similar
situation with TRAILR1- and TRAILR2-targeting antibodies.
It has been found that oligomerization or binding to Fcg-
receptors (FcgRs) strongly enhances the agonistic activity of
TRAILR1/2-specific antibodies.30–35 Most important, in vivo,
FcgRIIb is especially relevant to unleash the agonistic activity
of TRAIL death receptor-specific antibodies.34,35 The reason
for the prominent role of FcgRIIb presumably is based on its
favorable expression pattern compared with other FcgRs.
Now, the TRAILR1/2-targeting antibodies under investigation
in clinical trials (Conatumumab, Mapatumumab, Tigatuzumab,
PRO957890, CS-1008) are of the IgG1 isotype, which has only
a very low affinity for FcgRIIb. The capacity of these antibodies
to trigger TRAIL death receptor signaling in patients is therefore
probably also low.
Here, we describe the construction of fusion proteins
consisting of a llama-derived CD70-specific scFv, and
TRAILR1 and TRAILR2 discriminating TRAIL variants. These
bifunctional proteins not only overcome the poor activity of
soluble TRAIL in a CD70-restricted manner but also interfere
with CD70–CD27 interaction, which in CD70þ -cancers may
have protumoral activities.
Results
CD70 cell surface expression. CD70 expression in the
healthy organism is strongly restricted to T cells, some types
of B cells and NK cells. Reports showing strong expression of
CD70 in B-cell lymphomas and various types of solid tumors
defined this molecule as a potential target for tumor
therapy.11–14 Most data on CD70 expression are based on
immunohistochemistry techniques that do not discriminate
between cell surface and intracellularly expressed CD70. We
thus screened initially a large panel of tumor cell lines with
respect to cell surface expression of CD70 by FACS
(Table 1). B-cell lymphoma cell lines were with high
frequency (490%) strongly positive for cell surface-
expressed CD70, whereas only a subfraction of glioblastoma,
pancreatic, ovarian, renal and melanoma cell lines was
positive for cell surface CD70.
Table 1 Cell surface expression of CD27 and CD70 in cancer cell lines
Cell line Type CD70 CD27
Raji NHL þ þ þ þ þ þ
U266 MM þ þ þ 
Amo-1 MM þ þ þ 
RPMI MM þ þ  /þ
INA6 MM  
KMS-11 MM þ þ 
MM1.S MM þ þ 
KMS12.BM MM þ þ þ þ þ þ
JNN3 MM þ þ þ 
Mino MCL þ þ þ 
Jeko-1 MCL þ þ þ 
Rec-1 MCL þ þ þ 
Granta-519 MCL þ þ þ þ
MJ(G11) CTCL þ þ þ 
JVM3 CLL þ þ þ 
Ramos-Ra1 Burkitt þ þ þ þ þ
BJAB Burkitt þ þ þ  /þ
Daudi Burkitt þ þ 
SuDHL6 DLBCL þ þ 
Panc-1 Pancreatic cancer þ þ þ þ
Panc89 Pancreatic cancer þ þ þ
PancTu1 Pancreatic cancer  
MiaPaca-2 Pancreatic cancer  
Colo357 Pancreatic cancer  
A498 RCC þ þ þ 
786-O RCC þ þ þ þ
FaDu SCC  
HLaC-78 SCC  /þ 
WM-35 Melanoma  /þ 
WM-3211 Melanoma  
WM-115 Melanoma þ þ þ 
WM-1552C Melanoma þ /þ þ 
WM793 Melanoma  /þ 
WM-3248 Melanoma þ þ 
SK-mel-19 Melanoma  
MV3 Melanoma  
WM-852 Melanoma þ 
WM-451-LU Melanoma  
WM-1205Lu Melanoma þ þ þ 
BLM Melanoma  
OAW-42 Ovarian cancer  /þ 
SKOV-3 Ovarian cancer þ 
OVCAR3 Ovarian cancer þ þ 
GaMG Glioblastoma  /þ 
U87 Glioblastoma þ 
U343 Glioblastoma þ 
Ln18 Glioblastoma  
Abbreviations: CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell
lymphoma; DLBCL, diffuse large B-cell lymphoma;MCL,mantle cell lymphoma;
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RCC, renal cell
carcinoma; SCC, squamous cell cancer. Cells were analyzed by using FACS.
þ þ þ indicates very high expression, for example, like Mino cells (Figure 5A),
þ þ indicates high expression, for example, like OVCAR3 cells
(Figure 5A),þ indicates significant expression,  indicates lack of significant
binding
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Initial characterization of a novel llama-derived human
CD70-specific antibody. By screening for binding to
recombinant human CD70, we isolated the human CD70-
specific antibody 27B3, designated in the following as
lahCD70, from an antibody phage display library constructed
from peripheral blood cells of IIamas immunized with the
human renal cell carcinoma cell line 786-O. 1ahCD70 blocks
CD70–CD27 interaction with high efficiency and in this
respect is at least as potent as 1F6 (Figure 1a), another
CD70-specific antibody for which sequence information is
available from public patent databases (US 2006/
0083736A1) and for which a drug-conjugated variant (SGN-
75) is currently under clinical investigation (http://clinicaltrials.
gov). We further confirmed the inhibitory effect of lahCD70
on CD70-CD27 interaction in a functional assay where
CD70-expressing cells (U266 and Mino) have been used to
stimulate CD27 on HT1080 cells stably transfected with this
receptor.36 Activation of CD27 in the HT1080-CD27 cells
results in an increase in IL8 production. As expected,
lahCD70 and 1F6 inhibited the increase in IL8 production
by HT1080-CD27 cells, which was induced by coculturing
with CD70-expressing U266 or Mino cells (Figure 1b).
For binding studies, we generated a monomeric and a
trimeric fusion protein of the scFv variant of lahCD70 with
the Gaussia princeps luciferase (GpL). Trimerization of
scFv:lahCD70 was achieved by fusing the C terminus of
the scFv to the trimerization domain of tenascin-C (TNC).
The highly traceable GpL domain was furthermore intro-
duced to facilitate binding studies with the scFv:lahCD70
variants. Cellular equilibrium binding studies with the mono-
meric scFv:lahCD70 protein and the trimeric scFv:lahCD70-
TNC-GpL molecule on Mino and OVCAR3 cells yield KD
values of 2300 and 1300 pM for the monomeric scFv variant
and of 160 and 240pM for the trimeric variant (Figure 1c).
In sum, these data not only confirmed the high affinity of
lahCD70 for cells expressing CD70 but also demonstrated the
principle functionality of the corresponding scFv upon TNC-
driven trimerization. The latter was important as it was intended
in the following to use a TNC-stabilized variant of TRAIL for the
construction of CD70-targeted TRAIL fusion proteins.
Characterization of TRAILR1- and TRAILR2-specific
TRAIL mutants by cellular binding studies. It was
envisaged in this study to equip a blocking CD70-specific
Figure 1 CD70-specific mAb lahCD70 is a potent inhibitor of CD27–CD70 interaction. (a) OVCAR3 and Mino cells were preincubated (1 h) with the indicated concentrations of
the CD70-specific mAbs lahCD70 and 1F6. Cells were then incubated with 200 ng/ml CD27-Fc-GpL for an additional hour and after removal of unbound molecules cell-associated
GpL activity was determined. (b) Mino and U266 cells were preincubated (1 h) with the indicated concentrations of the CD70-specific mAbs lahCD70 and 1F6 and were then used
to stimulate IL8 production in HT1080-CD27 cells that were cultured in a 96-well plate. Next day, cell culture supernatants were analyzed for the presence of IL8 by ELISA.
(c) Monomeric and trimeric GpL fusion proteins of a lahCD70-derived scFv were used for equilibrium binding studies with OVCAR3 and Mino cells
scFv-targeted receptor-specific TRAIL mutants
J Trebing et al
3
Cell Death and Disease
scFv with TRAIL as well as TRAILR1- and TRAILR2-specific
TRAIL mutants for three reasons. First aim was to overcome
the limited activity of soluble TRAIL by anchoring to CD70.
The second intention was to link this with inhibition of CD70-
mediated protumoral activities. Third, against the back-
ground of the safe and also limited activity of the TRAIL
death receptor-targeting reagents currently under clinical
investigation (see introduction), it appears possible that cell
surface-anchoring TRAIL variants with high-specific activity
cause unanticipated side effects on nontransformed cells not
recognized so far. In this speculative case, the use of TRAIL
death receptor-specific TRAIL mutants could serve as an
option to reduce potential side effects related to activation of
the TRAIL death receptor type not relevant for apoptosis
induction in the targeted tumor type. Indeed, several types of
tumors are particularly sensitive for apoptosis induction via
one of the two TRAIL death receptors; for example, chronic
lymphocytic leukemia (CLL) and pancreatic tumors are
particularly TRAILR1 sensitive.37–39 Moreover, there is initial
evidence from a recent study that TRAIL death receptor-
specific mutants have higher specific activity than the wild-
type molecule.40 Therefore, we introduced recently published
mutations in our basic TNC-TRAIL construct conferring
specificity for TRAILR1 (G131R/R149I/S159R/N199R/
K201H/S215D) and TRAILR2 (Y189Q/R191K/Q193R/
H264R/I266L/D267Q).40,41 The receptor specificity of these
TRAIL mutants has so far mainly been analyzed by cell-free
approaches. We therefore analyzed the TRAIL receptor
usage of TRAILmutR1 and TRAILmutR2 in cellular equili-
brium binding studies. For this purpose, we tagged the TNC-
TRAIL variants with an N-terminal luciferase (GpL) domain
and performed equilibrium binding studies with HEK293
cells transiently transfected with TRAILR1, TRAILR2,
TRAILR3 and TRAILR4. Mock-transfected HEK293 cells,
which express no TRAILR1 and TRAILR3 and which have
only moderate expression of TRAILR2 and TRAILR4
(Supplementary Figure 1), were analyzed in parallel to
determine nonspecific binding. For GpL-TNC-TRAIL, we
obtained KD values for TRAILR1 and TRAILR2 of 3450 and
880pM. The KD value of interaction of GpL-TNC-TRAILmutR1
with TRAILR1 was 2590pM (Figure 2a). There was also
significant binding to TRAILR2-transfected cells with
GpL-TNC-TRAILmutR1, but the maximal specific binding
was significantly lower than with GpL-TNC-TRAILmutR2 and
GpL-TNC-TRAIL (Figure 2a). This suggests that the binding is
not primarily caused by binding to TRAILR2 but rather reflects
Figure 2 Analysis of TRAIL receptor binding of TRAILR1 and TRAILR2 discriminating TRAIL mutants. (a) Hek293 cells, which express endogenous TRAILR2 and
TRAILR4, were transiently transfected with expression constructs encoding the four types of cell-bound TRAIL receptors. Next day, equilibrium binding studies were performed
at 37 1C with GpL-TNC-TRAIL, GpL-TNC-TRAILmutR1 and GpL-TNC-TRAILmutR2. Mock-transfected cells served to determine non-specific binding. (b) Equilibrium binding
studies were performed with Jurkat cells, which only express TRAILR2 and the various GpL-TRAIL fusion proteins. Cells pretreated with 5mg/ml TRAIL were used for
determination of nonspecific binding. (c) Black 96-well ELISA plates were coated with protein G (0.5mg/ml) and loaded with TRAILR1(ed)-Fc or TRAILR2(ed)-Fc (B1mg/ml)
or remained untreated for determination of non-specific binding. After removal of unbound molecules, the indicated concentrations of GpL-TNC-TRAIL, GpL-TNC-
TRAILmutR1 and GpL-TNC-TRAILmutR2 were added for 1 h at 37 1C, and finally the well-associated luciferase activity was quantified. (d) HT29 cells were incubated (2 h, 37)
with Fc-fusion proteins of the various TRAIL variants and were then immunoprecipitated by help of protein G agarose. Immunoprecipitates and cell lysates were analyzed by
western blotting with respect to the presence of the indicated proteins. Lysates of untreated cells were supplemented with 10 ng of the corresponding Fc-fusion protein and
served as a negative control
scFv-targeted receptor-specific TRAIL mutants
J Trebing et al
4
Cell Death and Disease
binding to endogenous TRAILR4 and/or heterocomplexes of
TRAILR2 and TRAILR4. Indeed, GpL-TNC-TRAILmutR1, in
contrast to GpL-TNC-TRAIL and GpL-TNC-TRAILmutR2,
failed to bind to Jurkat cells, which only express TRAILR2
(Figure 2b).42 The affinity of the interaction of GpL-TNC-
TRAILmutR2 with TRAILR2 was 720 pM, whereas there was
no detectable binding to TRAILR1 (Figure 2a). GpL-TNC-
TRAILmutR1 also interacted with TRAILR3 and TRAILR4,
whereas GpL-TNC-TRAILmutR2 failed to bind TRAILR3
(Figure 2a). The efficient discrimination of GpL-TNC-TRAIL-
mutR1 and GpL-TNC-TRAILmutR2 between the two TRAIL
death receptors was also evident from in vitro binding studies
with immobilized TRAILR1-Fc and TRAILR2-Fc (Figure 2c).
To further prove that the huge preference of GpL-TNC-
TRAILmutR1 and GpL-TNC-TRAILmutR2 for TRAILR1 and
TRAILR2 indeed translates into discriminated death receptor
signaling, we performed immunoprecipitation experiments.
For these purposes, we used Fc-fusion proteins of TRAIL,
TRAILmutR1 and TRAILmutR2. The fusion of the various
TRAIL variants with the human IgG1 Fc domain resulted in
the formation of hexameric proteins and not only allowed
easy immune precipitation of ligand-bound receptor com-
plexes but also substituted for the known need of oligo-
merization of soluble trimeric TRAIL variants to achieve optimal
activity.26,27 In accordance with the results from the binding
studies, there was practically no TRAILR2 in Fc-TRAIL-
mutR1 immunoprecipitates and no detectable levels of
TRAILR1 in Fc-TRAILmutR2 immunoprecipitates, whereas
both receptors were easily detectable in immunoprecipitates
of Fc-TRAIL-stimulated cells (Figure 2d). We also analyzed
cell death induction using the TNC-TRAIL variants with and
without anti-Flag mAb M2 oligomerization in the Jurkat T-cell
line, which as mentioned above only expresses TRAILR2,
and with Mino and OVCAR3 cells that both express TRAILR1
and TRAILR2 (Figure 3a). Viability assays as well as western
blot analysis of caspase processing confirmed the strong
TRAILR1/TRAILR2 preference of the TRAILmutR1 and
TRAILmutR2 variants (Figures 3b and c). As observed in
former studies,43 anti-Flag oligomerization of the Flag-tagged
TNC-TRAIL variants resulted in a strong increase in cell
death induction (Figure 3b).
scFv:lahCD70-TRAIL variants display CD70-restricted
activation of TRAILR1 and TRAILR2. We and others
previously found that cell surface antigen-specific scFv-
TRAIL fusion proteins not only allow targeting of TRAIL
activity to tumor antigen-expressing cells but also that the
TRAIL domain exerts a higher apoptosis-inducing activity
upon cell surface antigen binding.27,44–49 Thus, scFv-TRAIL
fusion proteins showed a prodrug-related behavior, whereby
the latently present apoptotic activity of the TRAIL effector
molecule is unleashed by sole antigen–scFv domain inter-
action. The latter reflects that some members of the TNF
receptor family are potently activated by the membrane-
bound form of their ligand but fail to respond properly to
binding of soluble ligand trimers. Indeed, the inability of
soluble trimeric TRAIL variants to trigger robust TRAILR2-
mediated apoptosis is well established.26,27 To evaluate the
extent to which a prodrug-like activation of TRAILR1 and
TRAILR2 can be achieved with CD70-targeted scFv fusion
TRAIL fusion proteins, we constructed derivatives of
TNC-TRAIL, TNC-TRAILmutR1 and TNC-TRAILmutR2
bearing N-terminally scFv:lahCD70 as a CD70-targeting
domain (Figures 4a and b). Initially, we transiently
expressed CD70 in the CD70-negative HT1080 cell line,
which expresses both TRAIL death receptors but mainly
signals via TRAILR2 and analyzed the apoptotic effect of
the various scFv-TRAIL fusion proteins. scFv:lahCD70-
TNC-TRAIL and scFv:lahCD70-TNC-TRAILmutR2 but not
scFv:lahCD70-TNC-TRAILmutR1 induced significant cell
death in CD70 and mock-transfected HT1080 cells. More
important, the ED50-value of scFv:lahCD70-TNC-TRAIL
and scFv:lahCD70-TNC-TRAILmutR2 for apoptosis induc-
tion in the CD70-transfected cells almost increased one order
of magnitude when binding to CD70 was blocked with a
conventional CD70-specific antibody, whereas CD70 blockade
showed no effect on the dose response relation of apoptosis
induction in the mock-transfected HT1080 cells (Figure 4c).
This indicated that binding to CD70 resulted in enhanced
activation of TRAILR2. Next, we analyzed the scFv-TRAIL
fusion proteins using CD70 Jurakt cells and Mino and
OVCAR3 cells showing endogenous CD70 expression
(Figure 5b). To uncover a potential CD70-restricted apoptotic
activity, cells were treated in the absence and presence of
conventional CD70-specific antibodies competing with
scFv:lahCD70 for CD70 binding. In contrast to the TNC-
TRAIL and TNC-TRAILmutR2 variants (Figure 3b), the
corresponding scFv:lahCD70-TRAIL fusion proteins showed
some cell death induction in Jurkat cells at higher concentra-
tions, but this was not affected by the cotreatment with the
blocking CD70 antibody (Figure 5c). Therefore, the moderate
CD70 binding-independent cytotoxicity of scFv:lahCD70-
TNC-TRAIL and scFv:lahCD70-TNC-TRAILmutR2 on Jurkat
cells most likely reflects the activity of a minor subspecies of
aggregated fusion proteins mimicking anti-Flag-activated
TNC-TRAIL. More important, in the CD70-expressing Mino
and OVCAR3 cells, the CD70-targeted scFv-TRAIL fusion
proteins triggered complete cell death at low concentrations
(1–10 ng/ml), and the dose response of cell death induction
shifted to 10- to 100-fold higher concentrations when access
to CD70 was blocked by competing a CD70 antibody
(Figure 5b). In agreement with enhanced TRAIL death
receptor activation upon CD70 binding, caspase-8 activation
and processing of the caspase-8 substrates BID and
caspase-3 by the various scFv-TRAIL fusion proteins were
significantly diminished by blockade of CD70 (Figure 5c).
Similarly, there was strongly reduced processing of the
effector caspase substrate PARP1 indicative for reduced
apoptosis (Figure 5c). We also evaluated the apoptotic
activity of mixtures of trimeric TNC-TRAIL with high
concentrations of scFv:lahCD70-TNC-GpL, the trimeric
variant of the scFv:lahCD70 antibody fragment already
described in Figure 1c. From these experiments, no evidence
could be found that CD70 blockade by scFv:lahCD70-TNC-
GpL interferes with cell death induction by TNC-TRAIL or
oligomeric TNC-TRAIL (Figure 6a). However, as expected,
scFv:lahCD70-TNC-GpL inhibited the apoptotic activity of
our scFv:CD70-TRAIL fusion proteins on CD70þ cells.
Therefore, when the CD70-targeting scFv domain and the
TRAIL domain are separated into two distinct molecules
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without change in the trimeric organization of the domains as
present in the TRAIL fusion proteins, there is no CD70-
dependent increase in the apoptotic activity of TRAIL. As
scFv:lahCD70-TNC-GpL is equally effective as our
scFv:lahCD70-TRAIL fusion proteins in CD70 binding, this
rules out that blocking of CD27–CD70 interaction or
triggering of reverse CD70 signaling contribute to cell death
induction by the scFv:lahCD70-TNC-TRAIL fusion proteins.
We also evaluated cell death induction by scFv:lahCD70-
TRAIL in Raji and KMS12BM cells, which coexpress CD70
and CD27 (Table 1, Figure 6b). There was again a strong
reduction in cell death induction when CD70 was blocked
with a competing CD70-specific antibody (Figure 6c), but the
effect of CD70 binding appears less strong in these cell lines
compared with the CD27-negative cell lines Mino and
OVCAR3. It is tempting to speculate that this is related to
the fact that the fusion protein has to compete here with
endogenous CD27 for CD70 binding but other factors (e.g.
different expression levels) cannot be fully ruled out.
Discussion
Targeting of CD70 and TRAIL death receptors to treat cancer
is currently evaluated in various preclinical studies and phase
I clinical trials. In case of CD70 targeting, it was the initial idea
to exploit the tumor-associated expression of CD70 to direct
antibody-dependent effector functions to tumor cells. The
recent recognition of the immune suppressive activities of
cancer cell expressing CD70, however, now also caused an
interest in CD70 blockade as a therapeutic option in cancer
therapy. In case of targeting of the two TRAIL death receptors,
the therapeutic rational was initially apoptosis induction in
tumor cells, but now there is evidence that the tumor
vasculature is similarly a useful TRAIL target structure.50
Figure 3 Apoptosis induction by TRAILR1 and TRAILR2 discriminating TRAIL mutants. (a) OVCAR3, Mino and Jurkat cells were analyzed with respect to cell surface
expression of TRAILR1 and TRAILR2 by FACS. (b) OVCAR3, Mino and Jurkat cells were challenged in triplicates with the indicated concentrations of Flag-TNC-TRAIL,
Flag-TNC-TRAILmutR1 and Flag-TNC-TRAILmutR2 in the presence and absence of 1mg/ml of the anti-Flag mAb M2. Next day, cellular viability was determined using the
MTT assay or crystal violet staining. OVCAR3 cells were challenged in the presence of 2.5mg/ml CHX, which sensitizes this cell line for apoptosis induction. (c) The indicated
cell lines were treated for 4–6 h with 100 ng/ml of the various Flag-TNC-TRAIL variants oligomerized with 1mg/ml of the anti-Flag mAb M2, and total cell lysates were assayed
by western blotting for the presence of the indicated proteins. OVCAR3 cells were again sensitized for apoptosis induction by CHX treatment
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Immunostimulation and cell death induction in tumor, or
tumor-associated, cells are two complementary and maybe
even synergistic aims in tumor therapy. Combination thera-
pies addressing both of these aims are therefore particularly
attractive. To obtain a single molecule that concomitantly
allows blockade of the immunosuppressive activities of tumor
cell expressing CD70 and stimulation of cell death in tumors,
we genetically fused TRAIL with the CD70-blocking
scFv:lahCD70 (Figure 1). Moreover, in view of former studies,
showing superior activity of cell surface antigen-bound TRAIL
fusion proteins compared with conventional soluble
TRAIL,27,44–49 we anticipated enhanced cell death induction
by the fusion protein when bound to CD70. In fact, the
resulting fusion protein, scFv:lahCD70-TNC-TRAIL, showed
the targeted combinatorial activities and not only blocked
CD27-CD70 interaction but also triggered cell death 10- to
100-fold more efficiently in the presence of cells expressing
CD70 (Figure 5). Superior receptor activation by interaction
with cell surface antigen-bound ligand molecules or naturally
occurring membrane-bound ligand molecules has also been
observed for various other members of the TNF receptor
family but does not represent a common feature of this
receptor family.28 To clarify whether both or only one of the
two TRAIL death receptors possess improved responsive-
ness to CD70-bound scFv:lahCD70-TNC-TRAIL, we intro-
duced published mutations in the TRAIL part of the molecule
that confer preference for TRAILR1 or TRAILR2 (Figures 2
and 3). Enhanced cell death induction upon CD70 binding
was found with the TRAILR1- as well as with the TRAILR2-
preference variant of scFv:lahCD70-TNC-TRAIL (Figure 5).
This suggests that the superior activity of CD70-bound (or
generally cell surface antigen-bound) TRAIL fusion proteins
can be exploited, irrespective of having tumors that are
only sensitive for one of the two TRAIL death receptors.
Figure 4 Initial characterization of scFv:CD70-TRAIL fusion proteins. (a) Scheme of scFv:lahCD70-TRAIL fusion proteins. scFv:lahCD70, CD70-specific scFv; F, Flag tag;
TNC, tenascin-C trimerization domain; TRAIL, TRAILmutR1 and TRAILmutR2, aa 95–281 of wild-type TRAIL and TRAILR1- and TRAILR2-specific mutants derived thereof.
(b) SDS-PAGE analysis of purified scFv:lahCD70-TNC-TRAIL fusion proteins (100 ng each). (c) HT1080 cells were transiently transfected with a CD70 expression construct
or empty vector. Next day, transfected cells were stimulated for an additional day with the indicated concentrations of scFv:lahCD70-TNC-TRAIL, scFv:lahCD70-TNC-
TRAILmutR1 and scFv:lahCD70-TNC-TRAILmutR2 in the presence and absence of a competing conventional CD70-specific antibody
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Figure 5 CD70-restricted apoptosis induction by scFv:lahCD70-TRAIL, scFv:lahCD70-TRAILmutR1 and scFv:lahCD70-TRAILmutR2. (a) The indicated cell lines were
analyzed by using FACS for CD70 cell surface expression. (b) OVCAR3, Mino and Jurkat cells were cultured in 96-well plates, and half of the cells were pretreated with 10mg/ml of a
scFv:lahCD70 competing conventional CD70-specific antibody. Cells were then challenged overnight in triplicates with the indicated concentrations of scFv:lahCD70-TNC-
TRAIL, scFv:lahCD70-TNC-TRAILmutR1 and scFv:lahCD70-TNC-TRAILmutR2. Finally, cellular viability was determined using the MTT assay or crystal violet staining.
OVCAR3 cells were challenged in the presence of 2.5mg/ml CHX, which sensitizes this cell line for apoptosis induction. (c) The indicated cell line cells were stimulated in the
presence and absence of the conventional CD70-specific antibody lahCD70 for 4–6 h with 100 ng/ml of scFv:lahCD70-TNC-TRAIL, scFv:lahCD70-TNC-TRAILmutR1 and
scFv:lahCD70-TNC-TRAILmutR2. Total cell lysates were analyzed by western blotting for processing of the indicated proteins
scFv-targeted receptor-specific TRAIL mutants
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Soluble TRAIL (Dulanermin) and various TRAIL death
receptor-specific IgG1 antibodies are currently under clinical
investigation and were found so far to be well tolerated24,29
even if applied in combination with other drugs. In view of the
limited activity of soluble TRAIL27,28 and the need of anti-
TRAIL death receptor antibodies to bind to FcgRIIb to become
strongly agonistic in vivo,34,35 this good tolerability is in
retrospect perhaps no surprise. Thus, more potent TRAIL
death receptor-targeting reagents, such as oligomerized
TRAIL, TRAIL fusion proteins with the capability to anchor
to the cell surface or engineered TRAIL death receptor
antibodies with high affinity for FcgRIIb may have the potential
to elicit improved anti-tumor activity, but this may come along
with a risk for so far not recognized side effects. In this context,
Figure 6 Blockade of CD70 has no effect on cell death induction by conventional TRAIL. (a) Mino cells were cultured in 96-well plates, and half of the cells were pretreated
with 5 mg/ml of scFv:lahCD70-TNC-GpL and then challenged overnight in triplicates with the indicated concentrations of TNC-TRAIL, TNC-TRAILmutR1 and TRAILmutR2 with
and without anti-Flag (1 mg/ml) oligomerization. Cellular viability was determined using the MTT assay. (b) FACS analysis of CD70 and CD27 expression of Raji and
KMS12.BM cells. (c) Raji and KMS12.BM cells were cultured in 96-well plates in the presence and absence of 10 mg/ml of a scFv:lahCD70 competing conventional
CD70-specific antibody and were stimulated overnight in triplicates with the indicated concentrations of the various scFv:lahCD70-TRAIL fusion proteins. Cellular viability was
determined using the MTT assay
scFv-targeted receptor-specific TRAIL mutants
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the fusion proteins presented in our study not only solve the
problem of poor specific activity of soluble TRAIL trimers by
cell surface anchoring but also reduce the danger of potential
side effects by using the tumor-associated target CD70 for this
purposes. The use of a CD70-blocking protein domain for cell
surface TRAIL anchoring furthermore links TRAIL death
receptor stimulation with a possibly breach of the tumor-
associated immune homeostasis. Indeed, recent findings
showed that CD27 activation reduces apoptosis of regulatory
T cells in the thymic medulla and also in CD70-expressing
solid tumors, and in the latter case this led to enhanced tumor
growth.21,51,52 Therefore, cancer types where the presence of
Tregs is of poor prognosis could be preferential targets for
CD70-targeted TRAIL fusion proteins. CD70-targeted TRAIL
constructs may also affect immune cells out of the tumor area
but to which extent this compromises potential anti-tumoral
activities of the CD70-targeting TRAIL fusion proteins can
ultimately only be verified in future animal studies with a
humanized immune system or using mouse CD70-targeted
TRAIL fusion proteins.
Material and Methods
Cell lines and reagents. The INA6 cell line was a gift from Martin Gramatzki
(Kiel, Germany) and has been described elsewhere.53 All other cell lines were
obtained from the German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany) or ATCC. Cells were cultivated in RPMI1640 medium
(PAA, Co¨lbe, Germany) supplemented with 10% heat-inactivated fetal bovine
serum (PAA). For cultivation of INA6 cells, recombinant human IL6 (ImmunoTools,
Friesoythe, Germany) was added to the medium to a reach a concentration
of 10 ng/ml.
Molecular cloning, production and purification of recombinant
proteins. A pCR3-based (Invitrogen) expression plasmid encoding for Flag-
TNC-TRAIL with an Ig leader sequence has been published elsewhere.43
To introduce published mutations that allow discrimination of TRAILR1 and TRAILR2
binding, the TRAIL part in pCR3-Flag-TNC-TRAIL was replaced by synthetic genes
encoding corresponding TRAIL fragments harboring the mutations of interest. The
TRAIL mutant Y189Q/R191K/Q193R/H264R/I266L/D267Q for which strongly
reduced TRAILR1 binding has been reported41 was designated in the following as
TRAILmutR2, and the TRAIL mutant G131R/R149I/S159R/N199R/K201H/S215D for
which strongly reduced binding to TRAILR2 has been published40 was termed
TRAILmutR1. To obtain the Gaussia princeps luciferase (GpL) fusion proteins of the
various TRAIL variants, the Ig leader sequence in the pCR3-Flag-TNC-TRAIL
expression constructs was changed with a DNA fragment encoding a humanized
version of GpL including the molecules authentic leader sequence. The CD70-
specific human IgG1 antibody 1F6 was cloned with the help of a synthetic gene
designed according to the published sequences of the variable domains of this
antibody (US 2006/0083736A1) and sequences encoding the constant region of
human IgG1 (accession number P01857) and the constant domain of the V-J-C
segment of the immunoglobulin kappa chain (accession number AAA59000).
To obtain lahCD70 (27B3), a Fab fragment phage library derived from llamas
immunized with 786-O cells (ATCC) was screened for antibodies interfering with
CD70-CD27 interaction and high affinity for CD70 essentially as described
elsewhere.54 The variable regions of lahCD70 were linked with expression
cassettes of the constant regions of the human lambda light chain and the IgG1
region heavy chain. To generate expression plasmids for the scFv:lahCD70-TNC-
TRAIL variants, a synthetic gene encoding the Ig leader followed by the VH and VL
region of lahCD70 connected by a (GGGGS)3-linker was used to replace the Ig
leader encoding sequence of the corresponding pCR3-Flag-TNC-TRAIL plasmids.
The expression plasmid for CD27-Fc-Flag-GpL was obtained by insertion of an
expression cassette encoding the extracellular domain of CD27 including leader
sequence (aa 1–191) followed by aa 244–469 of hIgG1 (accession number
AF019036), a Flag tag and GpL devoid of its leader sequence into the Hind3 and
Xba1 sites of pCR3. To obtain TRAILR1(ed)-Fc and TRAILR2(ed)-Fc, amplicons
encoding the extracellular domains of these proteins were linked to the Fc domain of
hIgG1 in the pCR3 expression vector. The various secretable proteins were
transiently produced in Hek293 cells as recently described elsewhere.55 In brief,
1 ml of suspended Hek293 cells (40 106/ml) were electroporated (250 V,
1800mF, maximum resistance, Easyject Plus electroporator (PeqLab, Erlangen,
Germany) with 40mg of the corresponding expression plasmid, recovered overnight
in cell culture medium with 10% FCS and then further cultivated in 2% FCS-
containing medium. After 5–7 days, supernatants were collected, cleared by
centrifugation and analyzed with respect to the concentration of the recombinant
proteins by anti-Flag western blotting or by assaying luciferase activity. The
scFv:lahCD70-TNC-TRAIL fusion proteins were purified by help of their internal
Flag tag by affinity chromatography on anti-Flag agarose according to the
recommendations of the supplier.
Equilibrium binding studies. To measure total binding, cells
(3–10 105 cells) were incubated for 1 h with increasing concentrations of
the GpL fusion protein of interest at 37 1C. Cells were then washed five times
with 1.5 ml icecold PBS in Eppendorf reaction tubes and assayed for cell-
bound GpL activity using the Gaussia Luciferase Assay Kit (New England
Biolabs GmbH, Frankfurt a. M., Germany) and a Lucy 2 Luminometer (Anthos
Labtec Instruments, Krefeld, Germany). In case of the equilibrium binding
studies with the GpL fusion proteins of the various TRAIL variants and Hek293
cells transiently transfected with the various TRAIL receptors, binding to cells
transfected with empty vector was considered as nonspecific binding due to
the low expression of the endogenous receptors. In case of equilibrium binding
studies with scFv:lahCD70-GpL and scFv:lahCD70-TNC-GpL, cells were preincu-
bated for 1 h with 10mg/ml of conventional competing CD70-specific antibodies to
obtain nonspecific binding. Specific binding values were calculated by subtraction of
nonspecific binding values from the corresponding total binding values. KD values
were derived from the specific binding values by nonlinear regression using
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). To determine the
binding of the various GpL-TRAIL fusion proteins to immobilized TRAIL death
receptors, black high bond 96-well ELISA plates were coated with protein G
(0.5 mg/ml) and subsequently loaded with TRAILR1(ed)-Fc- and TRAILR2(ed)-
Fc-containing cell culture supernatants (B1 mg/ml) for at least 1 h (RT). Wells
were then incubated with increasing concentrations of GpL-TNC-TRAIL, GpL-
TNC-TRAILmutR1 and GpL-TNC-TRAILmutR2 for 1 h at 37 1C. Unbound
molecules were removed by five washing cycles with PBS, and the well-
associated luciferase activities were finally assayed by help of the Gaussia
luciferase Assay Kit. Nonspecific binding data were derived from wells
incubated with supernatants of mock-transfected cells instead of TRAILR1/2-Fc.
KD values were again obtained by fitting the binding data to a one side specific
binding plot using GraphPad Prism5.
Heterologous competition assays with CD27ed-Fc-GpL. Cells
(3–10 105 cells) were incubated with mixtures of 200 ng/ml CD27ed-Fc-GpL and
increasing concentrations of anti-CD70 antibodies for 1 h at 37 1C. After washing
the cells five times with ice-cold PBS, cell-bound molecules were again quantified
by assaying GpL activity with the Gaussia Luciferase Assay Kit and a Lucy 2
Luminometer.
FACS analysis. Cell surface expression of CD70, TRAILR1 and TRAILR2
was determined by help of CD27 (clone 57703, BD), CD70 (clone Ki-24, BD),
TRAILR1 (clone 16803, R&D Systems, Wiesbaden-Nordenstadt, Germany),
TRAILR2 (clone 22235, R&D Systems), TRAILR3 (FAB6302P, R&D Systems)
and TRAILR4 (FAB633P, R&D Systems) specific antibodies along
with corresponding isotype-matched control antibodies using a FACSCalibur
(BD Biosciences, Heidelberg, Germany).
Cell death assay. Cells were seeded in 96-well plates (10 103/well for
adherent cell lines and 50 103/well for suspension cell lines) and were treated
the next day as described in the figure legends. The cellular viability of suspended
cells was determined with the help of the MTT assay and viability of adherent cells
was quantified by crystal violet staining. Measured data of cellular viability were
finally normalized by help of viability values of untreated control cells (100%) and
cells that were challenged with a toxic mixture of CD95L, TRAIL and
cycloheximide (0%).
IL8 Elisa. Cells supernatants were cleared by centrifugation and assayed for
their IL8 content by help of a commercially available ELISA kit (BD Biosciences)
according to the protocol of the manufacturer.
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Western blot analysis and silver staining. Cells were collected,
washed once in PBS and resuspended in Laemmli sample buffer. After vortexing
and heat denaturation at 901 for 5 min, samples were briefly centrifuged to pellet
insoluble cell debris and subjected to fractionation by SDS-PAGE. Proteins were
transferred to nitrocellulose membranes by semi-dry blotting, and the proteins of
interest were detected by help of appropriate primary antibodies, horseradish
peroxidase-conjugated secondary antibodies and the Pierce enhanced chemi-
luminescence (ECL) western blotting detection system (Thermo Fisher Scientific,
Bonn, Germany). Protein samples dedicated for silver staining were again
fractionated by SDS-PAGE, and subsequently the gels were processed with
the Pierce Silver Stain Kit (Thermo Fisher Scientific) according to the protocol of
the supplier.
Conflict of Interest
KS is an employee of arGEN-X BVBA and HW is a consultant of arGEN-X
BVBA. KS and HW are co-inventors of CD70-specific antibodies.
The remaining authors authors declare no conflict of interest.
Acknowledgements. This work was supported by the Deutsche Jose´
Carreras Leuka¨mie-Stiftung e.V. (R/06/17) and the Deutsche Forschungsge-
meinschaft (grant WA 1025/24-1). Mohamed El-Mesery is a German Egyptian
Research Long Term Scholarship (GERLS) holder funded by DAAD.
1. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity and tolerance.
J Leukoc Biol 2011; 89: 195–203.
2. Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of
CD27-CD70 interactions: the impact of signal strength in setting the balance between
adaptive responses and immunopathology. Immunol Rev 2009; 229: 216–231.
3. Camerini D, Walz G, Loenen WA, Borst J, Seed B. The T cell activation antigen CD27 is a
member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol
1991; 147: 3165–3169.
4. Chan FK. Three is better than one: pre-ligand receptor assembly in the regulation of TNF
receptor signaling. Cytokine 2007; 37: 101–107.
5. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M et al. CD27, a member of
the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated
protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing
kinase. J Biol Chem 1998; 273: 13353–13358.
6. Gravestein LA, Amsen D, Boes M, Calvo CR, Kruisbeek AM, Borst J. The TNF receptor
family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol 1998; 28:
2208–2216.
7. Prasad KV, Ao Z, Yoon Y, Wu MX, Rizk M, Jacquot S et al. CD27, a member of the tumor
necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.
Proc Natl Acad Sci USA 1997; 94: 6346–6351.
8. Yamamoto H, Kishimoto T, Minamoto S. NF-kappaB activation in CD27 signaling:
involvement of TNF receptor-associated factors in its signaling and identification of
functional region of CD27. J Immunol 1998; 161: 4753–4759.
9. Gerondakis S, Banerjee A, Grigoriadis G, Vasanthakumar A, Gugasyan R, Sidwell T et al.
NF-kappaB subunit specificity in hemopoiesis. Immunol Rev 2012; 246: 272–285.
10. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative
and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase.
Immunity 2004; 21: 477–489.
11. Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J et al.
Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene
expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005; 41:
1794–1801.
12. Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J. CD70:
a new tumor specific biomarker for renal cell carcinoma. J Urol 2005; 173: 2150–2153.
13. Ryan MC, Kostner H, Gordon KA, Duniho S, Sutherland MK, Yu C et al. Targeting
pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug
conjugate SGN-75. Br J Cancer 2010; 103: 676–684.
14. Wischhusen J, Jung G, Radovanovic I, Beier C, Steinbach JP, Rimner A et al. Identification
of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway
of human glioblastoma. Cancer Res 2002; 62: 2592–2599.
15. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW et al.
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy
is critically dependent on CD27 costimulation. Blood 2007; 109: 4810–4815.
16. Lorenz MG, Kantor JA, Schlom J, Hodge JW. Anti-tumor immunity elicited by
a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999; 10:
1095–1103.
17. Nieland JD, Graus YF, Dortmans YE, Kremers BL, Kruisbeek AM. CD40 and CD70
co-stimulate a potent in vivo antitumor T cell response. J Immunother 1998; 21: 225–236.
18. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ et al.
Control of established melanoma by CD27 stimulation is associated with enhanced
effector function and persistence, and reduced PD-1 expression of tumor infiltrating
CD8(þ ) T cells. J Immunother 2010; 33: 769–779.
19. Cormary C, Gonzalez R, Faye JC, Favre G, Tilkin-Mariame AF. Induction of T-cell
antitumor immunity and protection against tumor growth by secretion of soluble human
CD70 molecules. Cancer Gene Ther 2004; 11: 497–507.
20. Miller J, Eisele G, Tabatabai G, Aulwurm S, von Kurthy G, Stitz L et al. Soluble CD70:
a novel immunotherapeutic agent for experimental glioblastoma. J Neurosurg 2010; 113:
280–285.
21. Claus C, Riether C, Schurch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling
increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res
2012; 72: 3664–3676.
22. van Gisbergen KP, van Olffen RW, van Beek J, van der Sluijs KF, Arens R, Nolte MA et al.
Protective CD8 T cell memory is impaired during chronic CD70-driven costimulation.
J Immunol 2009; 182: 5352–5362.
23. Grewal IS. CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets
2008; 12: 341–351.
24. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the
TRAIL to successful cancer therapy? Predicting and counteracting resistance against
TRAIL-based therapeutics. Oncogene 2013; 32: 1341–1350.
25. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset,
progression and therapy. Nat Rev Cancer 2008; 8: 782–798.
26. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective
mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing
ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis
signaling. J Biol Chem 2005; 280: 2205–2212.
27. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U et al. Differential
activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface
antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001;
20: 4101–4106.
28. Wajant H, Gerspach J, Pfizenmaier K. Engineering death receptor ligands for cancer
therapy. Cancer Lett 2013; 332: 163–174.
29. Hellwig CT, Rehm M. TRAIL signaling and synergy mechanisms used in TRAIL-based
combination therapies. Mol Cancer Ther 2012; 11: 3–13.
30. Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K et al. Cooperation of the agonistic DR5
antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve
survival. Clin Cancer Res 2008; 14: 7733–7740.
31. Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D et al. TRAIL signals
to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1
whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.
Br J Haematol 2007; 139: 568–577.
32. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S et al. A novel humanized
anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without
toxicity in hepatocytes. Ann Oncol 2008; 19: 1060–1067.
33. Zinonos I, Labrinidis A, Lee M, Liapis V, Hay S, Ponomarev V et al. Apomab, a fully human
agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic
breast cancer. Mol Cancer Ther 2009; 8: 2969–2980.
34. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D et al. An Fcgamma
receptor-dependent mechanism drives antibody-mediated target-receptor signaling in
cancer cells. Cancer Cell 2011; 19: 101–113.
35. Li F, Ravetch JV. Apoptotic and antitumor activity of death receptor antibodies
require inhibitory Fcgamma receptor engagement. Proc Natl Acad Sci USA 2012; 109:
10966–10971.
36. Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K et al.
Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization
improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-
induced TNF receptor ligand. J Immunol 2009; 183: 1851–1861.
37. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Roder C et al. TRAIL signaling
is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
J Mol Med 2010; 88: 729–740.
38. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al.
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death
Differ 2005; 12: 773–782.
39. Stadel D, Mohr A, Ref C, MacFarlane M, Zhou S, Humphreys R et al.
TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic
carcinoma cells and profoundly enhanced by XIAP inhibitors. Clin Cancer Res 2010; 16:
5734–5749.
40. Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and
efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL
variants. Cell Death Dis 2010; 1: e83.
41. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective
mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res
2005; 65: 11265–11270.
42. Sprick MR, Weigand MA, Rieser E, Rauch CT, Juo P, Blenis J et al. FADD/MORT1 and
caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis
mediated by TRAIL receptor 2. Immunity 2000; 12: 599–609.
scFv-targeted receptor-specific TRAIL mutants
J Trebing et al
11
Cell Death and Disease
43. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W et al. Enforced covalent
trimerization increases the activity of the TNF ligand family members TRAIL and CD95L.
Cell Death Differ 2007; 14: 2021–2034.
44. Bremer E, Kuijlen J, Samplonius D, Walczak H, de Leij L, Helfrich W. Target cell-restricted
and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the
pancarcinoma-associated antigen EGP2. Int J Cancer 2004; 109: 281–290.
45. Bremer E, Samplonius DF, Peipp M, van Genne L, Kroesen BJ, Fey GH et al.
Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor
necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human
CD7. Cancer Res 2005; 65: 3380–3388.
46. Bremer E, Samplonius DF, van Genne L, Dijkstra MH, Kroesen BJ, de Leij LF et al.
Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and
enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for
human EGFR. J Biol Chem 2005; 280: 10025–10033.
47. deBruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA et al.
Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble
TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010; 9: 301.
48. Schneider B, Munkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H et al.
Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain
fusion proteins. Cell Death Dis 2010; 1: e68.
49. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M et al. Selective
induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion
protein. Cancer Immunol Immunother 2008; 57: 233–246.
50. Wilson NS, Yang A, Yang B, Couto S, Stern H, Gogineni A et al. Proapoptotic activation of
death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor
growth. Cancer Cell 2012; 22: 80–90.
51. Coquet JM, Ribot JC, Babala N, Middendorp S, van der Horst G, Xiao Y et al. Epithelial
and dendritic cells in the thymic medulla promote CD4þ Foxp3þ regulatory T cell
development via the CD27-CD70 pathway. J Exp Med 2013; 210: 715–728.
52. Riether C, Schurch C, Ochsenbein AF. Modulating CD27 signaling to treat cancer.
Oncoimmunology 2012; 1: 1604–1606.
53. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W et al. Gp130 and ras
mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for
plasmacytoma. Hematol J 2001; 2: 42–53.
54. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P et al.
A large non-immunized human Fab fragment phage library that permits rapid isolation and
kinetic analysis of high affinity antibodies. J Biol Chem 1999; 274: 18218–18230.
55. Fick A, Wyzgol A, Wajant H. Production, purification, and characterization of scFv TNF
ligand fusion proteins. Methods Mol Biol 2012; 907: 597–609.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
ShareAlike 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)
scFv-targeted receptor-specific TRAIL mutants
J Trebing et al
12
Cell Death and Disease
